Caribou Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $46.86M
- P/E (TTM)
- –
- Dividend yield
- –
About Caribou Biosciences
Biological Products, (No Diagnostic Substances), SIC 2836
Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing genome-edited cell therapies for patients with devastating diseases. Utilizing its proprietary CRISPR hybrid RNA-DNA (chRDNA) technology, the company engineers allogeneic, off-the-shelf chimeric antigen receptor (CAR)-T cell therapies designed to enhance precision and overcome the limitations of autologous cell therapies. Its clinical development pipeline features product candidates targeting hematologic malignancies, primarily vispacabtagene regedleucel (vispa-cel) for relapsed or refractory B cell non-Hodgkin lymphoma and CB-011 for relapsed or refractory multiple myeloma. The therapies are aimed at patients suffering from severe blood cancers who require accessible and prompt cellular interventions.
The company conducts clinical trials across multiple countries, having evaluated its programs in medical centers within the United States, Australia, and Israel. Product manufacturing is conducted through contract manufacturing organizations. While specific administrative headquarters are not stated in the provided text, its operational footprint includes clinical study locations spanning North America, the Middle East, and Oceania.
Summary of the business section of Caribou Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Caribou Biosciences, Inc.
- Founded
- 2011
- Headquarters
- Berkeley, CA
- Address
- 2929 7th Street, Suite 105 94710
- Phone
- (510) 982-6030
- Employees
- 97, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, San Francisco, California
Stock & identifiers
- Ticker
- CRBU
- Exchange
- Nasdaq
- IPO date
- Jul 23, 2021
- Shares outstanding
- 107M, Aug 7, 2026
- Public float
- $112.50M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1619856
- CUSIP
- 142038108
- ISIN
- US1420381089
- EIN
- 45-3728228
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Rachel E. Haurwitz | President and CEO, Director | 3,816,545 |
| Timothy P. Kelly | Chief Technology Officer | 73,125 |
| Barbara G. McClung | Chief Legal Officer | 481,564 |
| Tina M. Albertson | Chief Medical Officer | 68,523 |
| Ruhi Ahmad Khan | Chief Business Officer | 104,998 |
| Sriram Ryali | Chief Financial Officer | 72,360 |
| Steven Kanner | Chief Scientific Officer | 431,556 |
| Ryan Fischesser | VP of Finance and Controller | 118,854 |
| Natalie Sacks | Director | – |
| Ran Zheng | Director | – |
| Nancy Whiting | Director | – |
| Dara Richardson-Heron | Director | – |
| Scott Braunstein | Director | – |
| David Lee Johnson | Director | – |
| Andrew Guggenhime | Director | – |
Employees
Headcount reported in annual reports
“As of February 27, 2026, we had 97 total employees, all of whom were full-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 23, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 19, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |